EUVIMEDEUVIMED entdecken
CrossrefInfokarte

High Expression of Complement Component 5 ( C5 ) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients

Suvi Savola, Arto Klami, Samuel Myllykangas, Cristina Manara, Katia Scotlandi, Piero Picci, Sakari Knuutila, Jukka Vakkila

ISRN Oncology · 2011

DOI: 10.5402/2011/168712 ↗
AbstractBibliografische Angaben

Abstract

Background . Unlike in most adult-onset cancers, an association between typical paediatric neoplasms and inflammatory triggers is rare. We studied whether immune system-related genes are activated and have prognostic significance in Ewing's sarcoma family of tumors (ESFTs). Method . Data analysis was performed on gene expression profiles of 44 ESFT patients, 11 ESFT cell lines, and 18 normal skeletal muscle samples. Differential expression of 238 inflammation and 299 macrophage-related genes was analysed by t -test, and survival analysis was performed according to gene expression. Results . Inflammatory genes are activated in ESFT patient samples, as 38 of 238 (16%) inflammatory genes were upregulated ( P < 0.001 ) when compared to cell lines. This inflammatory gene activation was characterized by significant enrichment of macrophage-related gene expression with 58 of 299 (19%) of genes upregulated ( P < 0.001 ) . High expression of complement component 5 ( C5 ) correlated with better event-free ( P = 0.01 ) and overall survival ( P = 0.004 ) in a dose-dependent manner. C5 and its receptor C5aR1 expression was verified at protein level by immunohistochemistry on an independent ESFT tumour tissue microarray. Conclusion . Immune system-related gene activation is observed in ESFT patient samples, and prognostically significant inflammatory genes ( C5, JAK1 , and IL8 ) for ESFT were identified.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →